Heart valve repair patients: which blood thinner is safest?
NCT ID NCT06901466
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at 880 people who had a minimally invasive heart valve repair and also need long-term blood thinners. It compares taking just one blood thinner (rivaroxaban) versus taking two (rivaroxaban plus clopidogrel) to see which causes fewer bleeding problems over one year. The goal is to find the safest option for these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rivaroxaban and Clopidogrel (blood thinners)
What this could lead to
If it works, this could identify the safest blood thinner regimen after heart valve repair, reducing bleeding risks while preventing clots.
What could go wrong
This is a Phase 4 trial, so the drugs are already approved, but the best strategy is unknown. Bleeding complications remain a risk, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITRAL REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences, Fuwai Hospital
RECRUITINGBeijing, Beijing Municipality, 100037, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact